Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | MMP1 | P03956 | 1/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | MMP8 | P22894 | 1/20 | 0.65 |
| ▸ | MMP13 | P45452 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235173 | 1.00 | AR (0.67) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL95754 | 0.89 | GAA (0.66) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL641243 | 0.87 | SMN1; SMN2 (0.64) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL7445075 | 0.87 | GAA (0.64) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL2452111 | 0.87 | GAA (0.64) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL3917522 | 0.84 | AR (0.67) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL3625980 | 0.84 | L3MBTL1 (0.69) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL17077916 | 0.84 | L3MBTL1 (0.65) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL1575942 | 0.84 | GAA (0.64) | ARGAASMN1; SMN2CA2CA1 | |
| SCHEMBL28270283 | 0.84 | L3MBTL1 (0.65) | ARGAASMN1; SMN2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836130-B | Synthesis method of 3, 4-dihydrobenzothiadiazine compound | 嘉实（湖南）医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-116836130-A | Synthesis method of 3, 4-dihydrobenzothiadiazine compound | 嘉实（湖南）医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-10172827-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | disclosed |
| EP-2385829-B1 | PRO-NEUROGENIC COMPOUNDS | UNIV TEXAS (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20180127367-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-05-10 | — | — | US | disclosed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| CN-1349381-A | Sulfonamide derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-05-15 | — | — | CN | disclosed |
| US-5783699-A | MAY BE CONJUGATED TO ANTIGENS, HAPTENS, ANTIBODIES IN IMMUNOASSAYS | ABBOTT LABORATORIES (US) | 1998-07-21 | — | — | US | disclosed |
| US-5669819-A | IMMUNOASSAY | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| US-5565570-A | REACTING AMINE WITH SULFONYL HALIDE IN INERT SOLVENT IN PRESENCE OF BASE TO FORM METAL SALT OF SULFONAMIDE, ACYLATING WITH ACTIVATED PHENANTHRIDINE-6-CARBOXYLIC ACID TO FORM CHEMILUMINESCENT SALT | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| US-5545739-A | E.G., 5-METHYL-6-(N-2-CARBOXYETHYL-N=(2-CARBOXYETHYL)-PHENANTHRIDIN IUMCARBOXAMIDE CHLORIDE; IMMUNOASSAYS; STABILITY; SENSITIVITY | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5543524-A | FORMING A SULFONAMIDE FROM AND AMINE AND A SULFONYL HALIDE AND AND ACYLATING WITH A CARBONYL HALIDE OF AN ACTIVATED ACRIDINE SALT | ABBOTT LABORATORIES (US) | 1996-08-06 | — | — | US | disclosed |
| US-5468646-A | Chemiluminescent acridinium salts | ABBOTT LABORATORIES (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0273115-B1 | Chemiluminescent acridinium and phenanthridinium salts | ABBOTT LAB (US) | 1994-09-07 | — | — | EP | disclosed |
| US-4497828-A | 3-Nitro-4-methylbenzene sulfon-2-chloro-4-nitroanilide and fungicidal composition for the control of plant diseases containing same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172827-B2 | Pro-neurogenic compounds | DCX, GAP43, BDNF | AR 4203/4885GAA 3570/4885SMN1; SMN2 182/4885 |
| US-20180127367-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | AR 3839/4885GAA 963/4885SMN1; SMN2 50/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | AR 3839/4885GAA 963/4885SMN1; SMN2 50/4885 |
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | AR 3858/4885GAA 763/4885SMN1; SMN2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.